FLT3, NPM1, DNMT3α AND NRAS GENES

MUTATION IN ACUTE MYELOID LEUKAEMIA

IN HUSM

NORAINI BINTI MAT YUNUS

UNIVERSITI SAINS MALAYSIA

2015
FLT3, NPM1, DNMT3a AND NRAS GENES
MUTATION IN ACUTE MYELOID LEUKAEMIA IN
HUSM

by

NORAINI BINTI MAT YUNUS

Thesis submitted in fulfillment of the requirements for the degree of

Master of Science

September 2015
ACKNOWLEDGEMENT

Alhamdulillah, with all my gratitude, I would like to express my deepest thankfulness to my main supervisor Dr Muhammad Farid Johan for his motivation, excellent guidance and instruction towards this project. Also, I am deeply grateful to my co-supervisors, Professor Rosline Hassan and Dr Abdul Rahim Hussein, who have been so supportive and thank for their ideas, concepts and comments in which have had a remarkable influence on this research.

My sincere appreciation goes to my laboratory-mates, Asma, Diana, Hamid, Chua, Wardah, Khairol Naaim, Khalilah, Samhani, Zulhusni and Iwani as it was a great experience to complete this laboratory work together with all of them. I would also like to thank the staffs of the Haematology Department, School of Medical Science, Universiti Sains Malaysia, particularly to Miss Selamah and Miss Ang, for their guidances and details in molecular laboratory work.

Special thanks to my parents (Mat Yunus Dollah and Na’amah Ismail) for their kind support in taking care of my kids (Muhammad Al-Haafiz and Muhammad Al-Faateh) and pray during my study. A largest thank is owed to my husband, Dr Muhd Al-Aarifin Ismail. He has provided a great love and support, giving financial aid and proof reading chapters, as well as keeps asking me when I would be finishing writing!
The school fee was supported by MyBrain15 from Ministry of Education (Malaysia) whereas monthly allowance has been supported by Graduate Assistant Scheme from Universiti Sains Malaysia. Deepest thanks to them for the financial support.

This project would be impossible without the active support of all these people mentioned here and others who is not mentioned specifically. Thanks to all.

NORAINI BINTI MAT YUNUS
Hematology Department,
School of Medical Sciences, Universiti Sains Malaysia,
Kubang Kerian, Kelantan.
September 2015
CONTENTS

ACKNOWLEDGEMENT ...........................................................................................................II

CONTENTS ................................................................................................................................IV

LIST OF TABLES ......................................................................................................................VIII

LIST OF FIGURES ..................................................................................................................X

ABBREVIATIONS ..................................................................................................................XII

LIST OF PUBLICATIONS ........................................................................................................XVI

ABSTRAK .................................................................................................................................XVII

ABSTRACT .................................................................................................................................XIX

CHAPTER 1 .................................................................................................................................... 1

INTRODUCTION .......................................................................................................................1

1.1 Acute Myeloid Leukaemia ..................................................................................................1

1.1.1 Definition .......................................................................................................................1

1.1.2 Clinical manifestations and diagnosis ............................................................................1

1.1.3 AML classification .........................................................................................................2

1.1.4 Epidemiology of AML in Malaysia ................................................................................6

1.2 Genetic pathogenesis in AML ..........................................................................................6

1.2.1 Model of leukaemogenesis ..........................................................................................7

1.3 Molecularly Targeted Therapies ......................................................................................10

1.4 Rationale of the study ........................................................................................................12
1.5 Target Genes ......................................................................................... 13
  1.5.1 FLT3 gene ......................................................................................... 13
  1.5.2 NPM1 gene ......................................................................................... 17
  1.5.3 DNMT3a gene ...................................................................................... 22
  1.5.4 RAS gene .......................................................................................... 24
1.6 Objectives of the study ........................................................................... 27

CHAPTER 2 ..................................................................................................... 28

METHODOLOGY ............................................................................................. 28
  2.1 Subjects and samples ........................................................................... 28
  2.2 Materials .................................................................................................. 29
    2.2.1 Chemicals and reagents ................................................................. 29
    2.2.2 Kits and consumables ................................................................. 30
    2.2.3 Laboratory equipments ............................................................. 30
    2.2.4 Preparation of buffers and solutions ........................................ 31
  2.3 Methods .................................................................................................. 32
    2.3.1 Isolation of genomic DNA .......................................................... 32
    2.3.1a From peripheral blood ............................................................. 32
    2.3.1b From bone marrow slide ......................................................... 33
    2.3.2 Quantitation of DNA concentration .......................................... 34
    2.3.3 Polymerase Chain Reaction (PCR) ........................................... 34
      2.3.3a Primer design ................................................................. 34
      2.3.3b Synthesis of primer ............................................................ 35
      2.3.3c DNA sequence profile ....................................................... 37
# LIST OF TABLES

Table 1.1: FAB classification system of AML (Lowenberg et al., 1999). .......................... 4
Table 1.2: WHO classification system of AML (Vardiman et al., 2009). ......................... 5
Table 2.1: Chemicals and reagents. .................................................................................... 29
Table 2.2: Kits and consumables. ....................................................................................... 30
Table 2.3: Laboratory equipments. ..................................................................................... 30
Table 2.4: The primer names, exon number, primer sequences and PCR product size for desired gene amplification ............................................................................... 36
Table 2.5: The chromosome location, region of base, size of amplified gene and NCBI reference sequence of desired studied gene. ................................................................. 37
Table 2.6: Constituents for PCR and its volume. ................................................................ 41
Table 2.7: PCR reaction. ...................................................................................................... 41
Table 2.8: Heteroduplex reaction ....................................................................................... 43
Table 2.9: CSGE gel constituents and its volume. ............................................................... 44
Table 3.1: Clinical data of 54 adult AML patients. ............................................................ 48
Table 3.2: \textit{FLT3}-ITD and \textit{NPM1} mutations in AML patients. ........................................ 49
Table 3.3: The definitions of coding DNA sequences that seen in exon 12 mutant \textit{NPM1} in this study ........................................................................................................ 70
Table 3.4: The definitions of un-coding DNA sequences that seen in intron 11 mutant \textit{NPM1} in this study ........................................................................................................ 71
Table 3.5: Clinical data of AML patients with/without \textit{FLT3}-ITD mutation ..................... 74
Table 3.6: The association of gender and \textit{FLT3}-ITD status .............................................. 74
Table 3.7: The association of age and \textit{FLT3}-ITD status .................................................. 75
Table 3.8: Clinical data of AML patients with/without NPM1 gene mutation.............76
Table 3.9: The association of gender and NPM1 mutation status.............................76
Table 3.10: The association of age and NPM1 mutation status..................................77
Table 3.11: Differences of overall survival of AML patients with/without FLT3-ITD ..78
Table 3.12: Differences of overall survival of AML patients with/without NPM1 mutation ............................................................................................................................................78
LIST OF FIGURES

Figure 1.1: “Two-hit” model of leukemogenesis................................................................. 9
Figure 1.2: Venn diagram including a new class model of leukemogenesis. ............ 9
Figure 1.3: Structure of FLT3 and commonly occurring mutation sites in FLT3. .... 14
Figure 1.4: FLT3 receptor signaling in normal hematopoietic cell. ...................... 15
Figure 1.5: Diagram of the NPM1 mutation type A in exon 12................................. 18
Figure 1.6: Diagram of NPM1 gene, mutant NPM protein and normal NPM protein  
(Leung, 2010)................................................................................................................ 20
Figure 1.7: Accumulation of mutant NPM proteins in cytoplasm (Leung, 2010)........ 21
Figure 1.8: Structure of DNMT3a. ................................................................................. 23
Figure 1.9: Methylation of cytosine catalyzed by DNMT3a (Brenner and Fuks, 2006). 23
Figure 1.10: RAS signaling pathway. ............................................................................ 24
Figure 1.11: The experimental strategies of this study .............................................. 47
Figure 3.1: CSGE analysis of FLT3-ITD....................................................................... 51
Figure 3.2: Sequence analysis of FLT3-ITD in case 6.................................................. 52
Figure 3.3: Sequence analysis of FLT3-ITD in case 10................................................ 53
Figure 3.4: Sequence analysis of FLT3-ITD in case 15............................................... 54
Figure 3.5: Sequence analysis of FLT3-ITD in case 33............................................... 55
Figure 3.6: Sequence analysis of FLT3-ITD mutation in case 47............................... 56
Figure 3.7: Sequence analysis of FLT3-ITD mutation in case 49............................... 57
Figure 3.8: Sequence analysis of FLT3-ITD mutation in case 53............................... 58
Figure 3.9: CSGE analysis of FLT3-TKD................................................................. 59
Figure 3.10: Sequence analysis of FLT3-TKD mutation in case 28 & 54................. 60
Figure 3.11: CSGE analysis of \textit{NPM1} ................................................................. 62
Figure 3.12: Sequence analysis of \textit{NPM1} in case 6 ............................................. 63
Figure 3.13: Sequence analysis of \textit{NPM1} in case 7 ............................................. 64
Figure 3.14: Sequence analysis of \textit{NPM1} in case 15 ............................................ 65
Figure 3.15: Sequence analysis of \textit{NPM1} in case 33 ............................................ 66
Figure 3.16: Sequence analysis of \textit{NPM1} in case 41 ............................................ 67
Figure 3.17: Sequence analysis of \textit{NPM1} in case 50 ............................................ 68
Figure 3.18: Sequence analysis of \textit{NPM1} in case 51 ............................................ 69
Figure 3.19: CSGE analysis of \textit{DNMT3a} ................................................................. 72
Figure 3.20: Sequence analysis of case 15 and 51 in \textit{DNMT3a} ............................... 73
Figure 3.21: Kaplan-Meier cumulative OS curves of AML patients carrying mutant \\
\textit{FLT3-ITD} and wild type \textit{FLT3} .......................................................................... 79
Figure 3.22: Kaplan-Meier cumulative OS curves of AML patients carrying mutant \\
\textit{NPM1} and wild type \textit{NPM1} .................................................................................. 80
Figure 4.1: ITD sequences in \textit{FLT3} exon 14. ............................................................. 83
ABBREVIATIONS

ADD    ATRX, DNMT3 and DNMT3L-type finger
AML    acute myeloid leukaemia
APML   acute promyelocytic leukaemia
ATRA   all-trans-retinoic acid
BAP    1,4-bis acryloylpiperazine
BM     bone marrow
bp     base pairs
°C     degree Celcius
CA     cytogenetically abnormal
CBF    core binding factor
CEBPA  CCAAT enhancer binding protein alpha
CI     confidence intervals
CN     cytogenetically normal
CRM1   chromosomal region maintenance 1
CSGE   conformation sensitive gel electrophoresis
del    deletion
DNA    deoxyribonucleic acid
DNMT3a DNA (cytosine-5')-methyltransferase 3 alpha
EDTA   ethylenediamine tetraacetic acid
FAB    French-American-British
FLT3   fms-like tyrosine kinase-3
FLT3-ITD+ FLT3-ITD mutant
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLT3-ITD</td>
<td>FLT3-ITD non-mutant</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>GDP</td>
<td>guanosine diphosphate</td>
</tr>
<tr>
<td>GRB2</td>
<td>receptor-bound protein 2</td>
</tr>
<tr>
<td>GTP</td>
<td>guanosine triphosphate</td>
</tr>
<tr>
<td>h</td>
<td>hour</td>
</tr>
<tr>
<td>Hb</td>
<td>haemoglobin</td>
</tr>
<tr>
<td>IDH</td>
<td>isocitrate dehydrogenase</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>ins</td>
<td>insertion</td>
</tr>
<tr>
<td>ITD</td>
<td>internal tandem duplication</td>
</tr>
<tr>
<td>JM</td>
<td>juxtamembrane</td>
</tr>
<tr>
<td>KI</td>
<td>kinase insert</td>
</tr>
<tr>
<td>M</td>
<td>Molar</td>
</tr>
<tr>
<td>MDS</td>
<td>myelodysplasia syndrome</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>min</td>
<td>minute</td>
</tr>
<tr>
<td>ml</td>
<td>millilitre</td>
</tr>
<tr>
<td>mM</td>
<td>millimolar</td>
</tr>
<tr>
<td>mm</td>
<td>millimeter</td>
</tr>
<tr>
<td>MPD</td>
<td>myeloproliferative disease</td>
</tr>
<tr>
<td>MRC</td>
<td>Medical Research Council</td>
</tr>
<tr>
<td>Mtase</td>
<td>methyltransferase</td>
</tr>
<tr>
<td>NES</td>
<td>nuclear export signal</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>NLS</td>
<td>nuclear localization signal</td>
</tr>
<tr>
<td>NoLS</td>
<td>nucleoli localization signal</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NRAS</td>
<td>neuroblastoma RAS</td>
</tr>
<tr>
<td>NPM1</td>
<td>nucleophosmin</td>
</tr>
<tr>
<td>NPM1⁺</td>
<td>NPM1 mutant</td>
</tr>
<tr>
<td>NPM1⁻</td>
<td>NPM1 non mutant</td>
</tr>
<tr>
<td>nt</td>
<td>nucleotide</td>
</tr>
<tr>
<td>µg</td>
<td>microgram</td>
</tr>
<tr>
<td>µl</td>
<td>microlitre</td>
</tr>
<tr>
<td>µM</td>
<td>micromolar</td>
</tr>
<tr>
<td>OD</td>
<td>optical density</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphoinositol-3 kinase</td>
</tr>
<tr>
<td>Plt</td>
<td>platelet</td>
</tr>
<tr>
<td>PWWP</td>
<td>proline-tryptophan-tryptophan-proline</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>RTK</td>
<td>receptor tyrosine kinase</td>
</tr>
<tr>
<td>rpm</td>
<td>revolutions per minute</td>
</tr>
<tr>
<td>SAM</td>
<td>s-adenosyl methionine</td>
</tr>
<tr>
<td>sec</td>
<td>second</td>
</tr>
<tr>
<td>SNP</td>
<td>single nucleotide polymorphism</td>
</tr>
<tr>
<td>SOS</td>
<td>son of sevenless</td>
</tr>
<tr>
<td>SSCP</td>
<td>single strand conformational polymorphism</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>TBE</td>
<td>tris borate-EDTA buffer</td>
</tr>
<tr>
<td>TEMED</td>
<td>tetramethylethylenediamine</td>
</tr>
<tr>
<td>TE</td>
<td>tris-EDTA buffer</td>
</tr>
<tr>
<td>TET2</td>
<td>tet methylcytosine dioxygenase 2</td>
</tr>
<tr>
<td>TKD</td>
<td>tyrosine kinase domain</td>
</tr>
<tr>
<td>TKI</td>
<td>tyrosine kinase inhibitor</td>
</tr>
<tr>
<td>Tm</td>
<td>melting temperature</td>
</tr>
<tr>
<td>TM</td>
<td>transmembrane</td>
</tr>
<tr>
<td>U</td>
<td>unit</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WT</td>
<td>wild-type</td>
</tr>
</tbody>
</table>
LIST OF PUBLICATIONS

Journal


Abstract in journal


Abstract in proceeding

Mutational analysis of FLT3, NPM1 and DNMT3A in patients with Acute Myeloid Leukaemia. 10th Malaysia Genetics Congress, 3rd-5th December 2013, Palm Garden Hotel IOI Resort, Putrajaya.

Abstracts in conferences

Conformational Sensitive Gel Electrophoresis (CSGE) as a method for NPM1 mutational screening in patients Acute Myeloid Leukemia. 1st International Conference on Molecular Diagnostic and Biomarker Discovery, 23th-25th October 2013, Equatorial Hotel, Penang, Malaysia.

Mutation analysis of FLT3-ITD, NPM1 and DNMT3A in AML patients at Hospital Universiti Sains Malaysia. 37th Annual Conference of the Malaysian Society for Biochemistry & Molecular Biology 18th -19th July 2012, Sime Darby Convention Centre, Kuala Lumpur.
MUTASI PADA GEN FLT3, NPM1, DNMT3a DAN NRAS DALAM LEUKEMIA MIELOID AKUT DI HUSM

ABSTRAK

Leukemia mieloid akut (AML) adalah sejenis penyakit yang jarang berlaku namun ia di antara penyakit yang paling kerap terjadi dalam kumpulan penyakit malignant darah dan selalu dikaitkan dengan kematian dalam kalangan orang dewasa. Mutasi pada gen FMS-tirosina kinase 3 duplikasi dalaman secara rawak (FLT3-ITD) dan nukleofosmin 1 (NPM1) merupakan mutasi genetik yang kerap berlaku dalam kalangan orang dewasa yang menghidapi AML dan masing-masing dikaitkan sebagai prognosis buruk dan prognosis baik. Data insiden mutasi bagi gen-gen mutasi yang lazimnya terlibat dalam kalangan pesakit AML dewasa masih belum diterbitkan. Dengan itu, kajian ini dijalankan adalah untuk menentukan frekuensi bagi gen FLT3-ITD, FLT3-TKD, NPM1, DNMT3a dan NRAS, jenis mutasi pada gen-gen tersebut, median kelangsungan hidup pesakit bagi kumpulan FLT3-ITD+/FLT3-ITD− dan NPM1+/NPM1− dalam masa 2 tahun, dan perhubungan antara parameter klinikal dengan mutasi gen FLT3-ITD dan NPM1 dalam kalangan pesakit AML dewasa di Malaysia. Dalam kajian ini, DNA daripada 54 pesakit dewasa AML yang baru diagnostisis diambil daripada Hospital Universiti Sains Malaysia di Kelantan. Kaedah PCR-CSGE telah digunakan untuk penyaringan mutasi pada gen FLT3-ITD dan NPM1 dalam kalangan pesakit AML. Frekuensi mutasi bagi gen FLT3-ITD dan NPM1 masing-masing adalah sebanyak 11% dan 13% yang mana frekuensinya adalah kurang berbanding data-data yang telah diterbitkan. Analisis jujukan menunjukkan kesemua mutasi pada gen FLT3-ITD dan NPM1 adalah unik
dalam setiap kes. Berdasarkan analisis tersebut, dua jenis mutasi yang dikenalpasti bagi gen FLT3 ekson 14 adalah ITD (sebanyak enam kes) dan bukan ITD (sebanyak satu kes). Kedua-dua jenis mutasi ini akan mengganggu fungsi ‘juxtamembrane’ pada FLT3, dengan itu mengakibatkan pengaktifan isyarat pertumbuhan secara terus-menerus. Menariknya, satu penemuan baru dikenalpasti dalam mutasi gen NPM1. Walaupun mutasi tersebut dijumpai di kawasan domain terminal C, mutasi tersebut tidak mengganggu motif NoLs pada protein NPM. Mutasi gen FLT3-ITD berkaitan secara signifikan dengan kehadiran peratusan blast yang tinggi (nilai \( p = 0.008 \)) dan kiraan sel darah putih yang lebih tinggi (nilai \( p = 0.023 \)) berbanding gen FLT3 yang normal. Manakala mutasi pada gen NPM1 pula dikaitkan secara signifikan lebih tinggi dalam kalangan wanita berbanding lelaki (nilai \( p = 0.038 \)). Tiada sebarang mutasi dikesan pada gen FLT3-TKD, DNMT3a, dan NRAS. Analisis kelangsungan hidup selama 2 tahun pesakit menunjukkan tiada perbezaan secara signifikan bagi keseluruhan kelangsungan hidup (OS) dalam kedua-dua kumpulan FLT3-ITD+/FLT3-ITD- (nilai \( p = 0.660 \)) dan NPM1+/NPM1- (nilai \( p = 0.714 \)). Walaupun OS dalam kumpulan FLT3-ITD+/FLT3-ITD- tidak menunjukkan perbezaan secara signifikan, median OS bagi pesakit AML yang mempunyai FLT3-ITD adalah lebih pendek berbanding pesakit yang mempunyai FLT3 yang normal (masing-masing 9 dan 52 minggu). Frekuensi bagi mutasi pada gen FLT3-ITD dan NPM1 adalah lebih tinggi dalam kalangan pesakit AML di Malaysia berbanding mutasi pada gen lain iaitu FLT3-TKD, DNMT3a, dan NRAS.
Acute myeloid leukaemia (AML) is a rare but the most common occurrence among hematologic malignancy and associated with the greatest mortality in adults. FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) and nucleophosmin 1 (NPM1) mutations are the most common genes mutation found in adult AML and have been associated with poor and good prognosis, respectively. Published data on the prevalence of FLT3-ITD and NPM1 mutations of AML adult patients in Malaysia are not available online. Thus, this study was conducted to determine the frequency of FLT3-ITD and NPM1 mutation as well as FLT3-TKD, DNMT3a, and NRAS, the types of mutations, two-years overall survival/median survival time of FLT3-ITD+/FLT3-ITD− and NPM1+/NPM1− group, and the related clinical data for mutant FLT3-ITD and NPM1 within the adult Malaysian AML patients. In this study, the genomics DNA from 54 newly diagnosed adult AML patients were retrieved from Hospital Universiti Sains Malaysia, Kelantan. Polymerase chain reaction followed by conformation sensitive gel electrophoresis (PCR-CSGE) technique was used to detect gene mutations in AML. The frequency of FLT3-ITD and NPM1 mutations were found to be 11% and 13%, respectively which were less compared to published data. With respect to sequence analysis, all of the mutant FLT3-ITD and NPM1 resulted in variety of amino acid sequences in every case. Based on the analysis, two types of mutation have been identified in FLT3 exon 14; ITD (six cases) and non-ITD (a single nucleotide deletion)
(one case). Both kind of mutations would disturb the juxtamembrane domain function in FLT3 receptor, thus activate the continuous growth signal. Interestingly, a different finding was found in NPM1 mutation. Although the mutation was identified in the coding region of C-terminal domain, the mutation does not disturb the NPM nucleolar localization signal (NoLs) motif. FLT3-ITD mutation was associated with a significantly higher blast percentage ($p$-value $= 0.008$) and white blood cell count ($p$-value $= 0.023$) than the FLT3 wild type. On the other hand, NPM1 mutation were found not to associate with blast percentage and white blood cell count but occurred significantly higher in female patients ($p$-value $= 0.038$). Mutation was not detected in FLT3-TKD, NRAS, and DNMT3a genes. Two years overall survival (OS) analysis indicated no significant difference in both group, $FLT3$-ITD+/$/FLT3$-ITD- ($p$-value $= 0.660$) and $NPM1$+/$/NPM1$- ($p$-value $= 0.714$). Although the OS in $FLT3$-ITD+/$/FLT3$-ITD- group showed not significantly difference, the median OS of AML patients with the $FLT3$-ITD was shorter than those with the wild type (9 versus 52 weeks, respectively). $FLT3$-ITD and $NPM1$ mutations were more prevalent in adult Malaysian AML patients compared to the other genes; $FLT3$-TKD, $DNMT3a$, and $NRAS$. 
CHAPTER 1
INTRODUCTION

1.1 Acute Myeloid Leukaemia

1.1.1 Definition

Acute myeloid leukaemia (AML) is heterogeneous with respect to clinical manifestation, therapy, cytogenetic rearrangement and genetic alteration. AML is defined as a clonal proliferation of immature haematopoietic progenitors (myeloblasts) with varying degree of myeloid differentiation in the bone marrow, peripheral blood, or extramedullary tissues (Vardiman et al., 2009).

1.1.2 Clinical manifestations and diagnosis

Clinical manifestations of AML result from proliferation (overproduction) of myeloid blast cells and bone marrow failure that leads to decrease in the production of normal blood cells; red blood cells (RBCs), other types of white blood cells (WBCs), and platelets. As a result of bone marrow failure, AML patients would have anaemia, neutropenia and/or thrombocytopenia manifested as fatigue, lethargy, dyspnea, fever, weight loss, infection and haemorrhage. AML progresses quickly and typically fatal within weeks or months if not treated (Hoffman et al., 2005).
The recent definitive diagnosis for AML requires bone marrow aspiration for morphologic examination to identify the presence of 20% or more blasts in the marrow. In rare cases, for blast count below than 20%, but if cytogenetic aberrations are present with a t(8;21)(q22;q22), inv(16)(p13.1q22), t(16;16)(p13.1;q22), or t(15;17)(q22;q12), it has to be considered as AML as well (Vardiman et al., 2009). Aside from that, cytochemistry, immunology and immunohistochemistry techniques are also used for confirmation of AML.

1.1.3 AML classification

Although AML patients share many common clinical manifestations, their leukaemic cell morphology, cytogenetics and molecular genetics are obviously heterogenous. Two systems have been commonly used to classify AML, the French-American-British (FAB) classification and the World Health Organization (WHO) classification.

The older FAB classification divided AML into eight subtypes, M0 through M7, based on the type of cell from which the leukaemia developed and its degree of maturity (Table 1.1). This classification was based primarily on leukemic cell morphology and cytochemical stains (Lowenberg et al., 1999).

The WHO classification of AML is a newer system that incorporates and relates morphology, cytogenetic, molecular genetic and immunologic marker (Table 1.2). Using WHO criteria, the diagnosis of AML is defined as at least 20% of blasts in the bone marrow (BM) required. However, it is not applicable if one of the chromosome
abnormalities such as t(8;21)(q22;q22), inv(16)(p13.1q22), or (15;17)(q22;q12) in acute pro-myelocytic leukemia (APML) is detected. The presence of these genetic abnormalities is sufficient for the diagnosis of AML without blast percentage (Vardiman et al., 2009). The WHO classification of AML is more universally applicable and prognostically valid.

Although WHO classification is more detailed and perhaps more useful today, the FAB classification system is still used in Malaysia. FAB classification can be achieved faster and easier as it is only based on morphological examination and cytochemical stains.
Table 1.1: FAB classification system of AML (Lowenberg et al., 1999).

<table>
<thead>
<tr>
<th>FAB subtype</th>
<th>Common name</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>Acute myeloblastic leukaemia with minimal maturation</td>
</tr>
<tr>
<td>M1</td>
<td>Acute myeloblastic leukaemia without maturation</td>
</tr>
<tr>
<td>M2</td>
<td>Acute myeloblastic leukaemia with maturation</td>
</tr>
<tr>
<td>M3</td>
<td>Acute promyelocytic leukaemia (APML)</td>
</tr>
<tr>
<td>M4</td>
<td>Acute myelomonocytic leukaemia</td>
</tr>
<tr>
<td>M4Eo</td>
<td>Acute myelomonocytic leukaemia with abnormal eosinophils</td>
</tr>
<tr>
<td>M5</td>
<td>Acute monocytic leukaemia</td>
</tr>
<tr>
<td>M6</td>
<td>Acute erythroid leukaemia</td>
</tr>
<tr>
<td>M7</td>
<td>Acute megakaryoblastic leukaemia</td>
</tr>
</tbody>
</table>
Table 1.2: WHO classification system of AML (Vardiman et al., 2009).

1. AML with recurrent genetic abnormalities
   - AML with t(8;21)(q22;q22); \textit{RUNX1-RUNX1T1}
   - AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); \textit{CBFB-MYH11}
   - APL with t(15;17)(q22;q12); \textit{PML-RARA}
   - AML with t(9;11)(p22;q23); \textit{MLLT3-MLL}
   - AML with t(6;9)(p23;q34); \textit{DEK-NUP214}
   - AML with inv(3)(q21q26) or t(3;3)(q21;q26.2); \textit{RPNI-EVII}
   - AML (megakaryoblastic) with t(1;22)(p13;q13); \textit{RB15-MKL1}
   - AML with mutated \textit{NPM1}
   - AML with mutated \textit{CEBPA}

2. AML with myelodysplasia-related changes

3. Therapy – related myeloid neoplasms (MRC)

4. AML, not otherwise specified (NOS)
   - AML with minimal differentiation
   - AML without maturation
   - AML with maturation
   - Acute myelomonocytic leukaemia
   - Acute monoblastic / monocytic leukaemia
   - Acute erythroid leukaemia
     - Pure erythroid leukaemia
     - Erythroleukemia, erythroid / myeloid
   - Acute megakaryoblastic leukaemia
   - Acute basophilic leukaemia
   - Acute panmyelosis with myelofibrosis

5. Myeloid sarcoma

6. Myeloid proliferations related to Down syndrome

7. Transient abnormal myelopoiesis

8. Blastic plasmacytoid dendritic cell neoplasm
1.1.4 Epidemiology of AML in Malaysia

The incidence of all leukaemia in the Asian population (7.5 per 100 000 population) is lower than that of the White population (13.5 per 100 000 population) (Howlader et al., 2014). In Malaysia leukaemia was the seventh most common cancer in females and fourth in males, with only 2.8 per 100,000 populations (Lim and Halimah, 2004). AML is a rare but it is the most common type of leukaemia in adults, and its incidence increases with age. The age of Malaysian AML at presentation ranged from four month to 81 years with median age of 39 years (Meng et al., 2013). Chromosome aberrations were detected in 30% Malaysian AML and the most common chromosome abnormalities are t(8;21), trisomy 8, and t(15;17) (Meng et al., 2013).

1.2 Genetic pathogenesis in AML

The heterogeneity of AML results from a complex network of chromosome aberrations and genetic mutations. Chromosome aberrations, revealed by GTG-banding (G bands by Trypsin using Giemsa) are found in 30-50% of AML patients. Genetic mutations occur both in cytogenetically normal AML (CN-AML) and in cytogenetically abnormal AML (CA-AML) patients (Grimwade and Hills, 2009). Lately, the genetic mutations are increasingly being recognized as important diagnostic and prognostic markers in AML. In parallel to this important insight, researchers nowadays are trying to develop targeted treatments based on interference with molecular genetics as well as epigenetic mechanisms.
1.2.1 Model of leukaemogenesis

Many of the mutations identified in AML when existing alone do not lead to leukaemogenesis. This is because at least two different types of mutations are required for the development of leukaemia. For many years back, the “two-hit” model of hypothesis by Gilliland (2001) was accepted as model of leukaemogenesis which suggested that development of AML required two different types of genetic mutations, class I (proliferative mutation) and class II (blocking mutation).

However recently, scientists discovered the presence of a new class of mutation (class III) involving epigenetic modifications to the AML genome would also contribute towards leukaemogenesis of AML and they cannot be categorized in class I or class II mutations (Figure 1.2). Epigenetics is defined as the study of heritable changes in gene expression that are not due to modifications in the DNA sequence. Class III mutations that confer epigenetic regulation includes genes which encode transcription like $DNMT3a$, $IDH1$, $IDH2$ and $TET2$ (Galm et al., 2006; Figueroa et al., 2009; Jiang et al., 2009; Barrero et al., 2012).

Class I mutations confer proliferation and survival advantage. They involve gene coding for receptor and non-receptor protein tyrosine kinase like $FLT3$ and $KIT$ as well as for proteins of GTPase activity such as $NRAS$, which affect proliferative signaling pathways, leading abnormal growth of leukemic cells (Kelly and Gilliland, 2002).
Class II mutations lead to arrest differentiation of myeloid progenitor cells by affecting genes of transcription factors. Genes coding for transcription factors become disrupted by their fusion, as a result of chromosome changes (AML1-ETO and PML-RARα), or by point mutation (NPM1 and CEBPA). This class of mutation occurs during early leukaemogenesis and is stable throughout the disease course. These mutations have been considered as initiating mutations (Kelly and Gilliland, 2002).

If mutations of class I (excessive myeloproliferation) or class II (differentiation arrest) of hematopoietic progenitors occur on its own, it results in the development of myeloproliferative syndrome (MPD) or myelodysplastic syndrome (MDS), respectively. When these two kinds of mutations occurring sequentially in a single cell, these two-hit lead to a fully penetrating AML (Figure 1.1) (Kelly and Gilliland, 2002).

AML with multilineage dysplasia was introduced in the WHO classification 2001 to enclose cases of AML characterized by myelodysplastic syndrome–like features. The WHO classification 2008 revised this group into a new category, AML with myelodysplasia-related changes (AML-MRC). The category now includes patients with at least 20% blasts in peripheral blood or bone marrow and any of the following: (1) AML arising from a previous MDS or mixed MDS/myeloproliferative neoplasm, (2) AML with a specific MDS-associated cytogenetic abnormality and/or (3) AML with multilineage dysplasia (Vardiman et al., 2009; Vardiman and Reichard, 2015).
Figure 1.1: “Two-hit” model of leukemogenesis.

Figure 1.2: Venn diagram including a new class model of leukemogenesis.
1.3 Molecularly Targeted Therapies

For over past 40 years, the induction treatment for AML has not changed. The standard induction chemotherapy for AML patients remains cytarabine and anthracycline combination, also known as 7+3 treatment. This treatment has been troubled by low survival rates (10% for 5 years) and deaths due to toxicity. For these reasons, the ability to identify specific patients who may get benefit from molecularly targeted therapies would give a great promise for AML to improve remission and cure rate. By screening for the presence of genetic mutations that are targeted by specific drugs, specific therapy would be given based on genetic abnormalities characteristic of the individual patient’s.

The first targeted therapy in AML was the use of all–trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APML/AML-M3) patients. This treatment specifically blocks PML-RARA fusion protein function and it appears curable in more than 70% of APML patients (Quignon et al., 1997).

A number of new targeted molecular therapies are still under study and clinical trials. FLT3 gene mutations is a potentially attractive marker towards molecularly targeted therapy in AML as they constitute 1/3 mutations in AML. Nowadays, researchers have explored in clinical trials of tyrosine kinase inhibitor (TKI) drugs, including lestaurtinib, sorafenib, sunitinib and midostaurin, which were shown to have in-vitro activity against FLT3 mutants. During therapy with FLT3 TKIs, the induction of acquired resistance has emerged as a clinical problem. Thus, the current focus in clinical research is to find out
the optimization of the targeted therapy and the potential treatment options to overcome resistance in this situation.

On the other hand, *NPM1* mutations which account in 50-60% of CN-AML show a great promise for minimal residual disease, as it is stable and persists at relapse (Mrozek *et al.*, 2007). It appears that *NPM1* mutations will become important markers for disease monitoring in patients with CN-AML.

The advent of these molecular agents provides us with a new approach toward AML treatment and monitoring.
1.4 Rationale of the study

Cytogenetic alterations have been recognized as the strongest predictive factor for AML patients’ response to therapy and survival for a long time. The lack of chromosome aberration in cytogenetically normal AML has proved challenging for the management of this clinically heterogeneous disease. However in recent years, several molecular markers in AML were discovered within a growing list of genes and allowed more precise prognostic predictions and therapeutic decisions. *FLT3* (exon 14-15 and 20) and *NPM1* (exon 12) genes have been chosen in this study because they are the two most extensively studied genes for their significant role in prognostic predictions of AML and they are the most commonly identified in AML throughout the world. Besides that, we also interested to look at the frequency and types of mutation in *DNMT3a* (exon 23) and *NRAS* (exon 1 and 2) genes. Unfortunately, we have limited information regarding the alteration of these genes in Malaysian AML patients, and also the correlation between these genes alteration status and the important clinical parameters associated with AML prognosis and treatment. Concerned with that, this study aimed to explore these genetic mutations in Malaysian AML cases particularly in the North Eastern State of the Peninsular Malaysia and it is truly hoped that the results obtained from this study would give us better understanding towards the molecular pathogenesis of AML in Malaysia; also would lead to improve diagnostic strategy as well as treatment outcome among Malaysian AML population.
1.5 Target Genes

1.5.1 FLT3 gene

The FLT3 (FMS-like tyrosine kinase receptor III) gene is mapped to chromosome 13q12 in humans and contains 24 exons. It encodes for the FLT3 receptor protein that belongs to class III receptor tyrosine kinase (RTKIII) and composed of 993 amino acids (Zuo et al., 2009). The FLT3 receptor is a membrane-bound RTK, which plays a crucial role in proliferation, differentiation and apoptosis of normal haematopoietic cells. It comprises five immunoglobulin-like domains (Ig-like) in the extracellular ligand binding region, a transmembrane domain (TM), a juxtamembrane domain (JM), two intracellular kinase domains (TKD1 and TKD2) divided by a kinase insert domain (KI), and a C-terminal domain (Figure 1.3) (Abu-Duhier et al., 2001a).

In normal haematopoietic cells, activation of FLT3 receptor is ligand-dependent. Figure 1.4 represents FLT3 receptor signaling in normal haematopoietic cell. In the absence of ligand, FLT3 receptor is an inactive conformation. Ligand binding to FLT3 receptor leads to dimerization on the cell membrane and conformational change of the receptor as well as rapid phosphorylation of tyrosine residues on the FLT3 receptor. This in-turn activates RAS and PI3K pathways. The activated FLT3 receptor interacts with growth factor-bound protein 2 (GRB2) through SHC and activates GRB2 which binds Son of Sevenless homolog 1 (SOS). The GRB2-SOS complex is recruited to the membrane associated RAS. This activates the MAPK pathway which includes RAF, MEK and ERK proteins. Ligand-stimulation of FLT3 activates the GRB2 associated protein 1/2
(GAB1/2), and also activates the PI3K-AKT pathway. Phosphorylated ERK and AKT result in activation of transcription factors involved in cell proliferation and anti-apoptosis, respectively. Mutation in the structure FLT3 receptor will lead to a continuous growth signal and promote leukaemogenesis (Kiyoi et al., 2002; Stirewalt and Radich, 2003).

Figure 1.3: Structure of FLT3 and commonly occurring mutation sites in FLT3.
Figure 1.4: FLT3 receptor signaling in normal hematopoietic cell.
Mutation in the *FLT3* accounts for 25% of all AML cases. They fall into two main categories of mutations; internal tandem duplications (*FLT3*-ITD) in JM and point mutations in TKD (*FLT3*-TKD) (Kiyoi *et al.*, 2002; Meshinchi *et al.*, 2008). *FLT3*-ITD is also known as *FLT3* length mutation (*FLT3*-LM). The length of the ITD varies from 3-400bp nucleotides (Stirewalt and Radich, 2003). *FLT3*-ITD accounted in 25% for adult (Frohling *et al.*, 2002; Schnittger *et al.*, 2002; Thiede *et al.*, 2002) and 15 % for pediatric (Meshinchi *et al.*, 2008). Another most common type of *FLT3* mutation is a point mutation at codon D835 (aspartate) or I836 (isoleucine) in exon 20 within the activation loop of TKD. *FLT3*-TKD usually is less frequently seen in AML and they account for 5% of adult and 3% of pediatric AML (Abu-Duhier *et al.*, 2001b; Yamamoto *et al.*, 2001). Both *FLT3*-ITD and *FLT3*-TKD result in ligand independent activation and leads to continuous activation of FLT3 receptor (Betz and Hess, 2010; Gulley *et al.*, 2010).

*FLT3*-ITD in AML patients confer poor prognosis which relates to high percentage of blast cells, increased risk of relapse from complete remission, and reduced survival (Kottaridis *et al.*, 2001; Frohling *et al.*, 2002; Small, 2006; Feng *et al.*, 2012). However, the prognosis of *FLT3*-TKD in AML is still unclear (Whitman *et al.*, 2010; Smith *et al.*, 2011). The high incidence of *FLT3* mutations as well as the poor prognosis status in AML eventually stimulated the development of specific treatment for *FLT3* aberration.
1.5.2  \textit{NPM1} gene

The nucleophosmin 1 (\textit{NPM1}) gene is located on chromosome 5q35 in humans and contains 12 exons. It encodes for the nucleophosmin (NPM) proteins which contains 294 amino acids. The NPM is a multifunntional nucleocytoplasmic shuttling protein localized mainly in the granular regions of the nucleolus (Cordell \textit{et al.}, 1999). It has several functions which are transporting ribosome components to the cytoplasm for ribosome biogenesis (Olson \textit{et al.}, 1986), controlling centrosome duplication during cell division (Okuda \textit{et al.}, 2000), and interacting with tumor-suppressors gene (p53 and p19Arf) for controlling cell proliferation and apoptosis (Colombo \textit{et al.}, 2002).

Mutations in \textit{NPM1} gene are documented in 26-30\% of whole adult AML cases (Falini \textit{et al.}, 2005; Roti \textit{et al.}, 2006; Boonthimat \textit{et al.}, 2008) and 40-60\% of adult CN-AML (Mrozek \textit{et al.}, 2007). Their incidences are lower among pediadiatric AML (7.5-8\%) (Bacher \textit{et al.}, 2010; Braoudaki \textit{et al.}, 2010). These mutations are restricted to exon 12 which encodes for the C-terminus of NPM protein and generally heterozygous. Various \textit{NPM1} gene mutations were reported in AML at nucleotide positions 956 through 971 (Chen \textit{et al.}, 2006; Boonthimat \textit{et al.}, 2008). All these mutations are either insertions or insertions/deletions producing the frameshift mutation in the C-terminus region of the \textit{NPM1} gene and these mutations arrest the protein production in the cytoplasm (Mardis \textit{et al.}, 2009).

More than 40 different mutations have been identified in exon 12 of the \textit{NPM1} gene. The most common type of mutations in \textit{NPM1} is a duplication of a TCTG between
position 956 and 959 and its accounts for 75% of the cases. Figure 1.5 represents the NPM1 mutations type A in C-terminal domain (Grisendi and Pandolfi, 2005).

Figure 1.5: Diagram of the NPM1 mutation type A in exon 12.

NPM1 mutations are related with an increased in WBCs count (Suzuki et al., 2005a; Yan et al., 2007; Boonthimat, 2008), female (Dohner et al., 2005; Schnittger et al., 2005; Thiede et al., 2006; Gale et al., 2008) and M4/M5 FAB subtypes (Kassem et al., 2011). NPM1 mutations generally coexist with FLT3-ITD (Dohner et al., 2005; Falini et al., 2005; Schnittger et al., 2005; Suzuki et al., 2005a; Verhaak et al., 2005). Only NPM1+/FLT3-ITD− compilation is recognized as favorable prognostic factor, especially in patients aged more than 70 years. AML with NPM1+/FLT3-ITD+ is related with poor prognosis, while AML with NPM1+/FLT3-ITD+ and NPM1+/FLT3-ITD− is associated with intermediate prognosis (Thiede et al., 2006; Bacher et al., 2010; Becker et al., 2010).

NPM1 functions are based on its nucleocytoplasmic shuttling process which is controlled by three important domains such as nuclear export signal (NES), nuclear
localization signal (NLS) and nucleoli localization signal (NoLS) (Figure 1.6). The NES is crucial for transportation of NPM protein from nucleoplasm into cytoplasm. The NLS and NoLS are crucial for localization of the NPM protein in nucleoplasm and nucleolus (Chen et al., 2006; Falini et al., 2007).

All NPM1 mutations have in a distinct sequence in the NPM protein at the C-terminal domain. All of them show loss of at least one of the tryptophan residues (W) at amino acid positions 288 and 290 at the C-terminal domain, which lead the frameshift mutations and create the common last 5 amino acid residues of VSLRK. The C-terminal tryptophans 288 and 290 are essentials for NoLS which is responsible for NPM nucleolar localization. The aberration disrupts the NoLS and also brings about an additional leucine-rich NES motif at the C-terminal. Both of them play crucial role in disrupting the normal nucleocytoplasmic transportation of the NPM protein and creating the abnormal cytoplasmic accumulation of the mutant NPM proteins (Figure 1.7) (Chen et al., 2006; Falini et al., 2007).

Falini et al. (2007) reported that cytoplasmic accumulation of the mutant NPM protein is NES dependent and normal NPM protein contains only one NES domain at amino acid position 92-104 (Figure 1.6) (Falini et al., 2006). It binds to the chromosomal region maintenance 1 (CRM1) export receptor and facilitates the downstream nuclear export of the normal NPM protein for normal functions. The mutant NPM protein however contains an extra creation of NES motif at C-terminal domain in which might reinforces the accessibility of the NPM mutants towards CRM1 receptor. It would leads to more
efficient nuclear export activity than the nuclear import activity and result in the uncontrolled cytoplasmic accumulation of NPM protein (Falini et al., 2007).

Figure 1.6: Diagram of NPM1 gene, mutant NPM protein and normal NPM protein (Leung, 2010).
Figure 1.7: Accumulation of mutant NPM proteins in cytoplasm (Leung, 2010).

1: Dislocation of the mutant NPM proteins from the nucleolus to the nucleoplasm due to disruption of the NoLS. 2: Dislocation of the mutant NPM proteins from the nucleoplasm to the cytoplasm due to the addition of NES in the C-terminal mutant NPM proteins.
1.5.3 *DNMT3a* gene

*DNMT3a* (DNA methyl transferase 3α) gene has 23 exons and maps to chromosome 2p23 in humans. *DNMT3a* gene encodes a DNA methyltransferase enzyme that is actively involved in epigenetic regulation. The DNMT3a enzyme contains three main domains structure, a proline-tryptophan-tryptophan-proline (PWWP) domain, an ATRX, DNMT3 and DNMT3L-type finger (ADD) domain, and the methyltransferase (Mtase) domain (Figure 1.8)(Weisenberger *et al.*, 2004). This enzyme localizes in the nucleus and uses S-adenosyl methionine (SAM) as the methyl group donor being transferred to the carbon 5 (C5) position of the cytosine ring in CpG dinucleotide in DNA (Figure 1.9). It is responsible for de novo methylation during mammalian development (Brenner and Fuks, 2006).

DNA methylation occurs mainly in the cytosine residues at the C5 positions of CpG dinucleotides and is important in regulating gene expression (Chen and Li, 2006). Aberrant DNA methylation plays a significant role in the pathogenesis of AML (Rosenbauer and Tenen, 2007).

*DNMT3a* gene mutations in AML accounted for 7-30% and were related to CN-AML, older age, M4/M5 FAB subtypes and poor prognosis (Ley *et al.*, 2010; Thol *et al.*, 2011; Hou *et al.*, 2012). Ho *et al.* (2011) demonstrated that frequency of *DNMT3a* mutations was rare in paediatric AML. The most frequently mutated site in *DNMT3a* is Aginine 882 (R882) residue located in the catalytic domain which led to reduced DNA methylation (Ley *et al.*, 2010; Thol *et al.*, 2011).
Figure 1.8: Structure of DNMT3a.

Figure 1.9: Methylation of cytosine catalyzed by DNMT3a (Brenner and Fuks, 2006).
1.5.4 **RAS gene**

The RAS proteins are a family of guanine nucleotide-binding proteins which have GTP/GDP binding and GTPase activity. They play important roles in regulatory processes including proliferation, differentiation as well as apoptosis (Stirewalt *et al.*, 2001).

Figure 1.10: RAS signaling pathway.